What You Need to Know About Gxp Independent Compliance Audits
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
The Gxp Dictionary 1St Edition
Testo Expert Knowledge The GxP Dictionary 1st edition Definitions relating to GxP and Quality Assurance 1 Note: Some of the information contained in this GxP Dictionary does not apply equally to all countries. Depending on the respective local legislation, other definitions may apply to certain terms and topics. The sections affected are not separately identified. 2 Foreword Efficacy, identity and purity are qual- This GxP Dictionary explains the ity attributes, which are required of majority of terms relating to GxP, products from the GMP-regulated qualification, validation and quality environment. The term “Good Manu- assurance. facturing Practice” sums up the quality assurance requirements from national It is intended as a compact reference and international regulations and laws. guide and aid for all those involved Other GxP forms have now been de- in GMP, and does not purport to be veloped, whose scope also expands complete. to adjacent sectors such as medical devices and life sciences. Testo SE & Co. KGaA The complex requirements of the “GMP compliance” generate a variety of specific concepts and abbrevia- tions. 3 GxP Dictionary Contents Contents 10 Terms and Definitions C 15 Calibration 0-9 15 CAPA 10 21 CFR 210/211 15 Capacity Test 10 483 15 CEP (Certificate of Suitability of Monographs of the European A Pharmacopoeia) 11 Action Limits 15 CFR 11 Active Pharmaceutical Ingredient 15 CFU (Colony-Forming Unit) (API) 16 cGMP 11 ADI (Acceptable Daily Intake) 16 Challenge Test 11 Airlock Concept 16 Change Control 11 Annex 16 Clean Corridor -
Introduction to Medical Device Law and Regulation March 2-4, 2021 | Live Virtual Event Speaker Biographies
Introduction to Medical Device Law and Regulation March 2-4, 2021 | Live Virtual Event Speaker Biographies DEBORAH BAKER-JANIS joined NSF International in 2013 after working in the medical device industry for over 10 years, including in both regulatory affairs and product development. Her experience includes the development of pre‐clinical testing protocols, risk documentation, quality system and regulatory affairs standard operating procedures, sales training materials, safety reports and domestic and international regulatory strategies and submissions. Ms. Baker‐Janis has supported the development and commercialization of a wide range of products including cardiovascular devices, general and plastic surgery devices, gastroenterology devices and general hospital devices. Her educational background is in biomedical engineering. MAHNU DAVAR is a partner in the Washington, DC office of Arnold & Porter. His practice focuses on assisting FDA-regulated entities with complex regulatory and compliance matters. He has represented early stage medical technology companies, clinical labs, major academic research institutions, and some of the largest multinational drug and device companies in the oncology, ophthalmology, pain, and diabetes care spaces. Mr. Davar routinely counsels clients on the regulatory and compliance aspects of promotional launch campaigns, clinical research, educational grants and charitable giving, manufacturing and supply chain, deal diligence, and other mission-critical activities. He has conducted significant compliance investigations and audits for business operations in the US, Europe, and Asia, and has extensive experience defending companies in criminal and civil healthcare fraud investigations. He has also assisted clients to prepare for and navigate state and federal regulatory inspections. Mr. Davar is a lecturer at the University of Pennsylvania Law School, a Fellow of the Salzburg Global Seminar, and a former Fulbright Scholar to India. -
Intertek Pharmaceutical Services
PHARMACEUTICAL SERVICES Laboratory & Assurance Solutions INTERTEK PHARMACEUTICAL SERVICES Total Quality Assurance for Pharmaceutical Development and Manufacturing Across your product lifecycle, our expertise brings you the insight you need to accelerate pharmaceutical, biopharmaceutical or medical device product development. Our assurance solutions allow you to identify and mitigate risks associated with products, processes, operational and quality management systems, assets and supply chains. Our specialists bring many years of experience across a variety of product areas including: • Innovative and Generic Pharmaceuticals • Orally Inhaled and Nasal Drug Products • Peptides, Proteins • Nutritional Products, Dietary • Biosimilars Supplements • Monoclonal Antibodies • Consumer Healthcare and Cosmetics • Antibody-drug Conjugates • Medical Devices • Oligonucleotide Therapeutics • Veterinary Medicines • Vaccines • Over-the-Counter (OTC) Drugs 2 Achieving Total Quality You can rely on our global network of experts, Assurance laboratories and specialists to deliver support We have delivered flexible including analysis, bioanalysis, formulation Our scientists, regulatory experts and auditors development, biologics characterization, contract services to the work with you at every stage of development specialist inhalation development expertise, global pharmaceutical and manufacturing, providing responsive, regulatory consultancy, risk assessment, quality compliant solutions. auditing and supply chain management industry for over 25 years At Intertek, -
NIHR CRN GCP Resources Document
NIHR CRN GCP Resource A compilation of links to useful on-line GCP quality tools and resources NIHR CRN Good Clinical Practice Reference Resource Acknowledgements This GCP Resource has been produced by Dr Stuart McCully of Compliance Healthcheck Consulting UK Ltd (www.chcuk.co.uk) on behalf on the National Institute of Health Research (NIHR) NIHR CRN Good Clinical Practice Reference Resource DISCLAIMER Although this GCP Resource contains information of a legal nature, it has been developed for information and education purposes only and does not constitute legal advice or opinions as to the current operative laws, regulations, or guidelines of any jurisdiction. In addition, because new standards are issued on a continuing basis, this GCP Resource is not an exhaustive source of all current applicable laws, regulations, and guidelines relating to non-interventional studies. While reasonable efforts have been made to assure the accuracy and completeness of the information provided, researchers and other individuals should check with the applicable National Competent Authorities and/or Research Ethics Committees before starting research activities. Copyright Information UK Statutory Instruments and Acts: Crown Copyright material is reproduced with the permission of the Controller of HMSO and the Queen’s Printer for Scotland. This information is licensed under the terms of the Open Government Licence (link) European Regulations, Directives and Guidelines: European Community Copyright material is reproduced with the permission of the European Commission. Version 3, May 2011 © NIHR CRN 2010 - 2011 3 NIHR CRN Good Clinical Practice Reference Resource Foreword The following document contains links to GCP-related articles, references, documents and websites and is aimed to serve as a resource to help develop and further your knowledge about Good Clinical Practice (GCP). -
Supply Chain Operations Audit
Building 243 University Campus Cranfield Bedford MK43 0AL Tel: +44 (0)1234 750323 Fax: +44 (0)1234 752040 www.scp-uk.co.uk Supply Chain Operations Audit by Dr. David Lascelles, Supply Chain Planning UK Limited High Impact Supply Chains Supply chain excellence has a real impact on business strategy. Supply chain management is a high impact mission that goes to the roots of a company’s very competitiveness. High-impact supply chains win market share and customer loyalty, create shareholder value, extend the strategic capability and reach of the business. Independent research shows that excellent supply chain management can yield: · 25-50% reduction in total supply chain costs · 25-60% reduction in inventory holding · 25-80% increase in forecast accuracy · 30-50% improvement in order-fulfilment cycle time · 20% increase in after-tax free cash flows That’s what we mean by high-impact. Does a high-impact supply chain leverage your business enterprise? Five Critical Success Factors Building a high-impact supply chain represents one of the most exciting opportunities to create value – and one of the most challenging. The key to success lies in knowing which levers to pull. Our research, together with practical experience, reveals that high-impact supply chains are, essentially, a function of five critical success factors: 1. A clear strategy: for the entire supply chain, tuned to market opportunities and focussed on customer service needs. 2. An integrated organisation structure: enabling the supply chain to operate as a single synchronised entity. 3. Excellent processes: for implementing the strategy, embracing all plan- source-make-deliver operations. -
SA 8000:2014 Documents with Manual, Procedures, Audit Checklist
D127: Demo of SA8000:2014 Documentation Kit Price 450 USD Total editable documentation package Complete editable document tool kit (Social manual, procedures, social policy, Social Committee, formats, SOPs, SA 8000 audit checklist etc.) ALL documents helps for certification to SA 8000-2014 Buy: www.Documentationconsultancy.com Chapter-1.0 CONTENTS OF SOCIAL ACCOUNTABILITY DOCUMENT KIT (More than 95 Editable document files in word/excel) A. The Total Editable Document kit has 8 main directories as below in Ms. word. D 127 – SA8000-2014 Document kit Sr. List of Directory Document of Details No. 1. Social Manual 07 files – 22 pages in Ms. word 2A. Procedures – Systems 08 procedures – 29 pages in Ms. word 2B. Procedures – OHS 09 procedures – 18 pages in Ms. word 3. Social Policy (English) 08 policies – 10 pages in Ms. word 4. Social Committee 08 files – 12 pages in Ms. word Formats / Templates 43 formats – approx. 50 pages in Ms. Name of departments Word OHS 17 formats in Ms. Word 5. Purchase (PUR) 05 formats in Ms. Word System and social accountability (SYS) 17 formats in Ms. Word Administration and Training (TRG) 05 formats in Ms. Word Standard Operating Procedures 6. 10 SOPs – 15 pages in Ms. word (SOPs) 7. Audit Checklist 03 files of more than 150 audit questions Total 96 files quick download in editable form by e delivery For more détails about SA8000:2014 Documentation Kit Features and Uses Click Here E-mail: [email protected] Tele: +91-79-2979 5322 Page 1 of 10 D127: Demo of SA8000:2014 Documentation Kit Price 450 USD Total editable documentation package Complete editable document tool kit (Social manual, procedures, social policy, Social Committee, formats, SOPs, SA 8000 audit checklist etc.) ALL documents helps for certification to SA 8000-2014 Buy: www.Documentationconsultancy.com Part: B. -
Guide to Inspections of Quality Systems
FOOD AND DRUG ADMINISTRATION GUIDE TO INSPECTIONS OF QUALITY SYSTEMS 1 August 19991 2 Guide to Inspections of Quality Systems This document was developed by the Quality System Inspec- tions Reengineering Team Members Office of Regulatory Affairs Rob Ruff Georgia Layloff Denise Dion Norm Wong Center for Devices and Radiological Health Tim Wells – Team Leader Chris Nelson Cory Tylka Advisors Chet Reynolds Kim Trautman Allen Wynn Designed and Produced by Malaka C. Desroches 3 Foreword This document provides guidance to the FDA field staff on a new inspectional process that may be used to assess a medical device manufacturer’s compliance with the Quality System Regulation and related regulations. The new inspectional process is known as the “Quality System Inspection Technique” or “QSIT”. Field investigators may conduct an ef- ficient and effective comprehensive inspection using this guidance material which will help them focus on key elements of a firm’s quality system. Note: This manual is reference material for investi- gators and other FDA personnel. The document does not bind FDA and does not confer any rights, privi- leges, benefits or immunities4 for or on any person(s). Table of Contents Performing Subsystem Inspections. 7 Pre-announced Inspections. ..13 Getting Started. .15 Management Controls. .17 Inspectional Objectives 18 Decision Flow Chart 19 Narrative 20 Design Controls. .31 Inspectional Objectives 32 Decision Flow Chart 33 Narrative 34 Corrective and Preventive Actions (CAPA). .47 Inspectional Objectives 48 Decision Flow Chart 49 Narrative 50 Medical Device Reporting 61 Inspectional Objectives 62 Decision Flow Chart 63 Narrative 64 Corrections & Removals 67 Inspectional Objectives 68 Decision Flow Chart 69 Narrative 70 Medical Device Tracking 73 Inspectional Objectives 74 Decision Flow Chart 75 Narrative 76 Production and Process Controls (P&PC). -
Social Accounting: a Practical Guide for Small-Scale Community Organisations
Social Accounting: A Practical Guide for Small-Scale Community Organisations Social Accounting: A Practical Guide for Small Community Organisations and Enterprises Jenny Cameron Carly Gardner Jessica Veenhuyzen Centre for Urban and Regional Studies, The University of Newcastle, Australia. Version 2, July 2010 This page is intentionally blank for double-sided printing. Table of Contents INTRODUCTION……………………………………………………………………..1 How this Guide Came About……………………………………………………2 WHAT IS SOCIAL ACCOUNTING?………………………………………………..3 Benefits.………………………………………………………………………....3 Challenges.……………………………………………………………………....4 THE STEPS………………………………………...…………………………………..5 Step 1: Scoping………………………………….………………………………6 Step 2: Accounting………………………………………………………………7 Step 3: Reporting and Responding…………………….……………………….14 APPLICATION I: THE BEANSTALK ORGANIC FOOD…………………….…16 APPLICATION II: FIG TREE COMMUNITY GARDEN…………………….…24 REFERENCES AND RESOURCES…………………………………...……………33 Acknowledgements We would like to thank The Beanstalk Organic Food and Fig Tree Community Garden for being such willing participants in this project. We particularly acknowledge the invaluable contribution of Rhyall Gordon and Katrina Hartwig from Beanstalk, and Craig Manhood and Bill Roberston from Fig Tree. Thanks also to Jo Barraket from the The Australian Centre of Philanthropy and Nonprofit Studies, Queensland University of Technology, and Gianni Zappalà and Lisa Waldron from the Westpac Foundation for their encouragement and for providing an opportunity for Jenny and Rhyall to present a draft version at the joint QUT and Westpac Foundation Social Evaluation Workshop in June 2010. Thanks to the participants for their feedback. Finally, thanks to John Pearce for introducing us to Social Accounting and Audit, and for providing encouragement and feedback on a draft version. While we have adopted the framework and approach to suit the context of small and primarily volunteer-based community organisations and enterprises, we hope that we have remained true to the intentions of Social Accounting and Audit. -
Chemical Management Audit Certification Supplier Management Verification Solutions
CHEMICAL MANAGEMENT AUDIT CERTIFICATION SUPPLIER MANAGEMENT VERIFICATION SOLUTIONS Intertek’s Chemical Management Audit solution is designed to help retailers and brands verify the safe handling and proper disposal of chemicals, in order to promote chemical management best practices throughout the global supply chain network. Your challenges, our solutions • Improved chemical management system unique techniques to best drive improvement Intertek’s Chemical Management Audit and practice through reduced environmental footprint, solution can help ensure effective chemical • Benchmarked results with global visibility increased efficiency and cost savings. management across your supply chain. The • Management transparency to enable This Chemical Management Audit is offered as process starts with an application of chemical targeted efforts. part of Intertek’s Supply Chain Solutions which expertise to provide a facility baseline risk help organizations all over the world manage • Identification of process efficiency and cost indicator, from which auditing of your facility compliance, risk, sustainability, and quality in savings can be efficiently planned. the supply chain. Intertek’s web-based platform and software • Assistance with green product design and helps ensure our Chemical Management certification Audit approach is the ideal tool for • Protect reputation risk, people and evaluating, tracking and monitoring chemical environment management performance in factories, Upon satisfactory completion of the chemical FOR MORE INFORMATION ultimately assuring overall performance management assessment and performance improvements. criteria, the manufacturer will receive a Intertek’s Chemical Management Audit report which details performance as well UK +44 116 296 1620 solution includes modular guidance for: as benchmarked comparisons with peers. The report showcases commitments of • Chemical Supply & Policy AMER +1 800 810 1195 moving towards zero discharge of hazardous • Management Practices chemicals. -
Good Clinical Practice (GCP)
Good Clinical Practice (GCP) Angela Del Vecchio 18 maggio 2018 1 Dichiarazione di trasparenza/interessi* Le opinioni espresse in questa presentazione sono personali e non impegnano in alcun modo l’AIFA Da 0 a Interessi nell’industria farmaceutica NO Attualmente oltre 3 anni precedenti 3 anni precedenti INTERESSI DIRETTI: 1.1 Impiego per una società: Ruolo esecutivo in una x obbligatorio società farmaceutica 1.2 Impiego per una società: Ruolo guida nello sviluppo x obbligatorio di un prodotto farmaceutico 1.3 Impiego per una società: altre attività x facoltativo 2. Consulenza per una società x facoltativo 3. Consulente strategico per una società x facoltativo 4. Interessi finanziari x facoltativo 5. Titolarità di un brevetto x facoltativo INTERESSI INDIRETTI: 6. Sperimentatore principale x facoltativo 7. Sperimentatore x facoltativo 8. Sovvenzioni o altri fondi finanziari x facoltativo 9. Interessi Familiari x facoltativo * Angela Del Vecchio, secondo il regolamento sul Conflitto di Interessi approvato dal CdA AIFA in data 25.03.2015 e pubblicato sulla Gazzetta Ufficiale del 15.05.2015 in accordo con la policy EMA /626261/2014 sulla gestione del conflitto di interessi dei membri dei Comitati Scientifici e degli esperti. N.B. <Per questo intervento non ricevo alcun compenso> DEFINITION Good Clinical Practice (GCP) is an international ethical and scientific quality standard for designing, conducting, recording and reporting trials that involve the partecipation of human subjects. Compliance with this standard provides public assurance that the rights, safety and well-being of trial subjects are protected and that the clinical trial data are credible. INTERNATIONAL CONFERENCE ON HARMONISATION (ICH) International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) is unique in bringing together the regulatory authorities and pharmaceutical industry of Europe, Japan and the US to discuss scientific and technical aspects of drug registration. -
Conflict of Interest Program Audit December 6, 2019
City of Edmonton Office of the City Auditor Conflict of Interest Program Audit December 6, 2019 1200, Scotia Place, Tower 1 10060 Jasper Avenue Edmonton, AB T5J 3R8 Phone: 780-496-8300 edmonton.ca/auditor REPORT SUMMARY Conflict of Interest Program Audit 2019 Governance Framework The definition, principles, and roles and Recommendation: Update the responsibilities in the Code of Conduct related to corporate conflict of interest conflicts of interest need to be enhanced to provide governance framework. additional processes and accountabilities to ensure conflicts of interests are understood, prevented, detected, and remediated appropriately. Guiding Documents Recommendation: Develop Conflict of interest guidance is embedded in clear guiding documents the Code of Conduct guiding documents. These specific to conflict of interest documents do not provide clear guidance on that are tailored to the City’s how to manage the conflict of interest risks to needs and risks. which the City is vulnerable. Training and Communication Recommendations: Conflict of interest training is included in • Ensure all employees have Code of Conduct training. Current records completed the Code of Conduct show that 67% of City of Edmonton training upon hiring. employees have completed mandatory • Provide on-going conflict of Code of Conduct training. Conflict of interest communication, and interest information and tools are difficult accessible information and tools. to find. 1 Report Highlights Background .......................................................................... -
Practical Risk-Based Guide for Managing Data Integrity
1 ACTIVE PHARMACEUTICAL INGREDIENTS COMMITTEE Practical risk-based guide for managing data integrity Version 1, March 2019 2 PREAMBLE This original version of this guidance document has been compiled by a subdivision of the APIC Data Integrity Task Force on behalf of the Active Pharmaceutical Ingredient Committee (APIC) of CEFIC. The Task Force members are: Charles Gibbons, AbbVie, Ireland Danny De Scheemaecker, Janssen Pharmaceutica NV Rob De Proost, Janssen Pharmaceutica NV Dieter Vanderlinden, S.A. Ajinomoto Omnichem N.V. André van der Biezen, Aspen Oss B.V. Sebastian Fuchs, Tereos Daniel Davies, Lonza AG Fraser Strachan, DSM Bjorn Van Krevelen, Janssen Pharmaceutica NV Alessandro Fava, F.I.S. (Fabbrica Italiana Sintetici) SpA Alexandra Silva, Hovione FarmaCiencia SA Nicola Martone, DSM Sinochem Pharmaceuticals Ulrich-Andreas Opitz, Merck KGaA Dominique Rasewsky, Merck KGaA With support and review from: Pieter van der Hoeven, APIC, Belgium Francois Vandeweyer, Janssen Pharmaceutica NV Annick Bonneure, APIC, Belgium The APIC Quality Working Group 3 1 Contents 1. General Section .............................................................................................................................. 4 1.1 Introduction ............................................................................................................................ 4 1.2 Objectives and Scope .............................................................................................................. 5 1.3 Definitions and abbreviations ................................................................................................